CYTH

Cyclo Therapeutics, Inc. (CYTH) | Rumor.io

Cyclo Therapeutics

CYTH

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about CYTH?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% new	0% new	0% 0

Feb 13

Cyclo Therapeutics, Inc. ($CYTH) is expected to break $1 today, with some targets as high as $132.
The stock has shown strength, with a MacD cross above and a holding trend on the 1-hour chart.
Price targets include $1.10, $3.30, $16.50, and $132, with some users suggesting a possible run to $1.50.

Generated by AI

Sentiment

Of the messages about CYTH that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100%	100%	100% +22.63
Bearish	—	0%	0%	0% -22.63

Bullish· Feb 7

Cyclo Therapeutics, Inc. (CYTH) has the potential to reach $2 or higher, with some predictions as high as $5 or more.
The company's market capitalization is relatively low, at less than $90 million, making it an attractive opportunity for institutions and analysts.
A gap up on Monday is expected, with some predicting a price of $10 or higher, and a potential squeeze to $2 or more.

Bearish· Feb 7

$CYTH's price has been overdue for a correction, with some investors waiting for it to "burst" at $1.09.
Cyclo Therapeutics, Inc. has reportedly run out of cash, making it a potential concern for investors.
The stock's price is expected to break below $1.15, with some investors anticipating a short position covering and a potential price drop.

Generated by AI

Topics

Of the messages about CYTH that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	42.11%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	57.89%

Announcements· Feb 7

Cyclo Therapeutics, Inc. ($CYTH) presents positive preliminary data from ongoing Phase 3 TransportNPC™ open-label sub-study in patients under 3 years old.
87% of patients in the study showed improvement or stabilization at 24 weeks, indicating a high response rate.
The data has led to multiple regulatory designations for Cyclo Therapeutics, with its shares up 36% following the announcement.

Technical Analysis· Feb 7

$CYTH is breaking out of a bull pennant and may continue to rise, with key levels at 1.25, 1.15, and 1.08.
The stock has formed a bull descending wedge and is curling off the pennant, with a potential big move coming.
Cyclo Therapeutics, Inc. ($CYTH) has significant daily and weekly volume, with a recent Phase 3 positive result and a parabolic continuation, suggesting volatility and a need for a well-planned trading strategy.

Generated by AI

Community

Of the messages about CYTH, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	0%	45.83%
Newcomers	—	100%	100%	54.17%

Regulars· Feb 7

Cyclo Therapeutics presents positive preliminary data from ongoing Phase 3 TransportNPC study in patients under 3 years old, with 87% showing improvement or stabilization at 24 weeks.
The TransportNPC study demonstrates a high response rate, with 87% of patients under 3 years old showing improvement or stabilization at 24 weeks.
Cyclo Therapeutics' TransportNPC study has received multiple regulatory designations, indicating its potential for future development and approval.

Newcomers· Feb 7

Many new users are excited about the asset's recent price increase, with one user calling it a "18075 record day" and another mentioning a "picture perfect" level at $1.30.
Some users are focused on the asset's recent positive news, including the presentation of preliminary Phase 3 data from an ongoing study, which they believe may lead to a "BIG move" on the chart.
Others are concerned about the asset's liquidity, with one user mentioning that they have to step away from their computer and don't like leaving positions unattended, while another warns that the company has "zero cash left" and implies that this may be a reason to sell.

Generated by AI

News

Zevra Therapeutics: Worthy Of An Initial Holding (NASDAQ:ZVRA)

2mo agoSeeking Alpha

Also Discussed

Investors talking about CYTH also mention

#	Name	Attention
1	Cassava Sciences Inc.SAVA	0%new
2	Annovis Bio, Inc.ANVS	0%0
3	INmune Bio Inc.INMB	0%0
4	ORTX - Orchard Therapeutics plc	——
5	Comstock Holding Companies, Inc.CHCI	0%0
6	MDVL - MedAvail Holdings, Inc.	——
7	Rafael Holdings Inc.RFL	0%0
8	CYTO - Altamira Therapeutics Ltd.	——
9	AMTI - Applied Molecular Transport Inc.	——
10	Moleculin Biotech, Inc.MBRX	0%0